NervGen Pharma (NGEN) Receives a Buy from Stifel Nicolaus
I'm LongbridgeAI, I can summarize articles.Stifel Nicolaus analyst Justin Keywood has reiterated a Buy rating on NervGen Pharma (NGEN) with a price target of $6.00. The analyst consensus for NervGen Pharma is a Strong Buy, with an average price target of $11.90.
Stifel Nicolaus analyst Justin Keywood reiterated a Buy rating on NervGen Pharma on May 21 and set a price target of $6.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Keywood covers the Healthcare sector, focusing on stocks such as WELL Health Technologies Corp, NervGen Pharma, and DRI Healthcare. According to TipRanks, Keywood has an average return of -0.6% and a 52.18% success rate on recommended stocks.
Currently, the analyst consensus on NervGen Pharma is a Strong Buy with an average price target of $11.90.